HIF‐2α regulates non‐canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma

• DOI: 10.1111/jcmm.13202
• Publication Date: 2017-05-25T17:04:31Z
• Authors: Wenzhu Li; Changhao Chen; Xiaohui Zhao; Huilin Ye; Yue Zhao; Zhiqiang Fu; Wenwei Pan; Shangyou Zheng; Lusheng Wei; Tianwen Nong; Zhihua Li; Rufu Chen
• Keywords: Male; 0301 basic medicine; Glutamine; Mice, Nude; Original Articles; Mechanistic Target of Rapamycin Complex 2; Middle Aged; 3. Good health; Gene Expression Regulation, Neoplastic; Pancreatic Neoplasms; 03 medical and health sciences; Cell Movement; Cell Line, Tumor; Lymphatic Metastasis; Basic Helix-Loop-Helix Transcription Factors; Animals; Humans; Female; Aspartate Aminotransferase, Cytoplasmic; Neoplasm Transplantation; Aged; Carcinoma, Pancreatic Ductal; Cell Proliferation; Neoplasm Staging

AbstractHypoxia‐inducible factor‐2α (HIF‐2α) plays an important role in increasing cancer progression and distant metastasis in a variety of tumour types. We aimed to investigate its biological function and clinical significance in human pancreatic ductal adenocarcinoma (PDAC). A total of 283 paired PDAC tissues and adjacent normal tissues were collected from patients who underwent surgery or biopsy at Sun Yat‐sen Memorial Hospital between February 2004 and October 2016. In this study, we noted that HIF‐2α expression was significantly up‐regulated in PDAC, positively associated with disease stage, lymph‐node metastasis and patient survival, and identified as an independent prognostic factor of PDAC patients. We demonstrated that HIF‐2α silencing could reduce proliferation, migration and invasion of PDAC cells in vitro. The similar effect on growth was demonstrated in vivo. Furthermore, we noted that knock‐down of HIF‐2α significantly decreased the expression of glutamate oxaloacetate transaminase 1 (GOT1). Importantly, we confirmed that the PI3K/mTORC2 pathway promoted GOT1 expression by targeting HIF‐2α. Our study validated HIF‐2α was an important factor in PDAC progression and poor prognosis and may promote non‐canonical glutamine metabolism via activation of PI3K/mTORC2 pathway. Targeting HIF‐2α represents a novel prognostic biomarker and therapeutic target for patients with PDAC.